Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

SCYX
SCYNEXIS, Inc.
stock NASDAQ

At Close
Jul 17, 2026 1:51:48 PM EDT
4.27USD-4.688%(-0.21)22,838
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-4.48)0
After-hours
Jul 17, 2026 4:35:30 PM EDT
4.33USD+1.405%(+0.06)1,161
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 6, 2022
01:03PM EST  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.   GlobeNewswire Inc
Dec 22, 2021
08:30AM EST  SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million   GlobeNewswire Inc
Dec 20, 2021
08:37AM EST  SCYNEXIS Says BREXAFEMME Added To Major National Formulary, Providing Access For Millions More Commercially Insured Patients   Benzinga
08:30AM EST  BREXAFEMME (ibrexafungerp tablets) Added to Major   GlobeNewswire Inc
Dec 15, 2021
08:39AM EST  European Medicines Agency Grants Orphan Medicinal Product Designation For SCYNEXIS; Innovative Antifungal Ibrexafungerp For Indication Of Invasive Candidiasis   Benzinga
08:30AM EST  -- Orphan medicinal product designation will provide at least 10 years of market exclusivity in the EU for ibrexafungerp for invasive candidiasis.   GlobeNewswire Inc
Dec 6, 2021
07:03AM EST  Scynexis to Initiate a Phase 3 Study of Oral Ibrexafungerp as a Step-Down Treatment for Invasive Candidiasis Following Meeting With FDA   Benzinga
07:00AM EST  SCYNEXIS Announces Agreement with FDA on Innovative Strategy for   GlobeNewswire Inc
Dec 3, 2021
04:30PM EST  SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
08:44AM EST  SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million   GlobeNewswire Inc
Dec 1, 2021
10:37AM EST  SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that BREXAFEMME (ibrexafungerp tablets) has been named as a Popular Science 2021 Best of Whats New award winner in the Health category.   GlobeNewswire Inc
Nov 29, 2021
08:30AM EST  SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET.   GlobeNewswire Inc
Nov 23, 2021
08:32AM EST  SCYNEXIS Says Pivotal Phase 3 VANISH-306 Trial Results Published In International Journal Of Obstetrics And Gynaecology Demonstrate Statistical Superiority Of BREXAFEMME Over Placebo For Vaginal Yeast Infection   Benzinga
08:30AM EST  -- Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological eradication, and clinical improvement at Day-10 compared to placebo-treated patients.   GlobeNewswire Inc
Nov 10, 2021
07:54AM EST  SCYNEXIS Q3 Net Loss C$1.252M vs Net Income C$2.081M In Same Qtr. Last Year.   Benzinga
07:34AM EST  SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
11:45AM EST  SCYNEXIS Announces Successful Completion Of Phase 1 Trial Evaluating Intravenous (IV) Formulation Of Ibrexafungerp   Benzinga
08:30AM EST  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the successful completion of a Phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of a liposomal intravenous (IV) formulation of ibrexafungerp in healthy subjects.   GlobeNewswire Inc
Nov 3, 2021
08:30AM EDT  SCYNEXIS to Provide a Corporate Update and Report Third Quarter   GlobeNewswire Inc
Oct 21, 2021
08:45AM EDT  SCYNEXIS Phase 3 VANISH-303 Trial Results Show Superiority Of Ibrexafungerp For Treatment Of Vaginal Yeast Infection   RTTNews
08:30AM EDT  SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in   GlobeNewswire Inc
Oct 13, 2021
01:38PM EDT  SCYNEXIS To Present Pooled Data Analysis Results Demonstrating Consistent Efficacy And Safety Outcomes Across Two Phase 3 VANISH Clinical Trials Of Oral Ibrexafungerp Therapy For Vaginal Yeast Infection At October Medical Conferences   Benzinga
08:30AM EDT  SCYNEXIS to Present Pooled Data Analysis Results Demonstrating   GlobeNewswire Inc
Oct 11, 2021
08:32AM EDT  SCYNEXIS Highlights Presentation Of Preclinical Data Supporting Potential Of Ibrexafungerp To Treat Mucormycosis   Benzinga
08:30AM EDT  -- In vivodata demonstrated response rate for ibrexafungerp similar to current standard of care options for the treatment of mucormycosis -- Combination of ibrexafungerp with current therapies showed significant enhancement in median survival time and overall survival when compared with standard of care monotherapies   GlobeNewswire Inc
Oct 7, 2021
08:15AM EDT  SCYNEXIS To Present Clinical Data From Ongoing FURI And CARES Studies At The 10th Trends In Medical Mycology Meeting Showing Oral Ibrexafungerp Provides A Favorable Therapeutic Response In Patients With Severe Fungal Infections   Benzinga
08:00AM EDT  SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES   GlobeNewswire Inc
Sep 30, 2021
08:02AM EDT  Antimicrobials Working Group Highlights Member Company Participation at IDWeek   PR Newswire
Sep 29, 2021
11:07AM EDT  Scynexis Presents Interim Ibrexafungerp Data In Hospital-Based Fungal Infections   Benzinga
08:42AM EDT  SCYNEXIS Highlights Presentation Of Interim Analysis From FURI At Virtual IDWeek 2021 Showing Favorable Therapeutic Response In Severe Hospital-Based Fungal Infections Treated With Oral Ibrexafungerp   Benzinga
08:30AM EDT  SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek   GlobeNewswire Inc
Sep 23, 2021
08:33AM EDT  SCYNEXIS To Present Data On Oral Ibrexafungerp At IDWeek 2021 From Interim Analyses Of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates In Patents With Mucocutaneous And Invasive Fungal Infections   Benzinga
08:30AM EDT  SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from   GlobeNewswire Inc
Sep 22, 2021
08:55AM EDT  SCYNEXIS Reports US Availability Of BREXAFEMME,Antifungal Class Of Therapy Approved By FDA For Vaginal Yeast Infections   RTTNews
08:31AM EDT  SCYNEXIS Reports US Availability Of BREXAFEMME   Benzinga
08:30AM EDT  -- First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including cloud-based pharmacy -- New treatment is fungicidal against Candida species, disrupting the fungal cell wall and killing the fungi causing the infection, rather than only inhibiting its growth   GlobeNewswire Inc
Sep 13, 2021
08:30AM EDT  SCYNEXIS Announces Hansoh Pharmas Application to   GlobeNewswire Inc
Sep 8, 2021
08:30AM EDT  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual investor conferences in September.   GlobeNewswire Inc
Aug 16, 2021
08:20AM EDT  SCYNEXIS Q2 EPS $(0.22) Up From $(0.64) YoY   Benzinga
08:00AM EDT  SCYNEXIS Reports Second Quarter 2021 Financial Results and   GlobeNewswire Inc
Aug 5, 2021
08:02AM EDT  Acurx Pharmaceuticals Joins the Antimicrobials Working Group   PR Newswire
Aug 2, 2021
05:00PM EDT  SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Jul 29, 2021
08:24AM EDT  SCYNEXIS Announces Two Oral Presentations On Pooled Data From The BREXAFEMME Phase 3 VANISH Program Demonstrating Consistent Efficacy In The Treatment For Vaginal Yeast Infections At The IDSOG 2021 Virtual Annual Meeting   Benzinga
08:00AM EDT  SCYNEXIS Announces Two Oral Presentations on Pooled Data from the   GlobeNewswire Inc
Jul 12, 2021
08:05AM EDT  SCYNEXIS Announces Three Oral Presentations Of Ibrexafungerp Demonstrating Clinical And In Vitro Activity Against Candida Species At The 31st ECCMID   Benzinga
08:00AM EDT  -- FURI and CARES presentations show ibrexafungerps strong clinical response in difficult-to-treat and refractory fungal infections in the hospital setting including Candida auris -- In vitro data demonstrates ibrexafungerps broad activity against 967 clinical Candida isolates from patients in Denmark, including strains resistant to echinocandins   GlobeNewswire Inc
Jul 7, 2021
08:30AM EDT  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Eric Francois, Chief Financial Officer, will present at Ladenburg Thalmanns virtual Healthcare Conference on July 14th, 2021.   GlobeNewswire Inc
Jul 2, 2021
04:01PM EDT  SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Jun 23, 2021
08:34AM EDT  SCYNEXIS Reports Will Launch Update For BREXAFEMME; To Host Call Tuesday, Jun. 29 At 12 p.m. EDT   Benzinga
08:30AM EDT  -- BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal class in over 20 years -- Commercial launch update call is scheduled for Tuesday, June 29th @ 12pm ET   GlobeNewswire Inc
Jun 11, 2021
12:44PM EDT  Exclusive: SCYNEXIS CEO, Marco Taglietti Is Now Interviewing On Benzinga's Power Hour Show   Benzinga
08:30AM EDT  -- Company presentation will highlight BREXAFEMME (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting   GlobeNewswire Inc
Jun 9, 2021
01:22PM EDT  Scynexis' Brexafemme For Vaginal Yeast Infections Secures 10 Years Regulatory Exclusivity   Benzinga
08:49AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Jun. 9, 2021: EA, WISH, SCYX, COIN, CLVS   Benzinga
08:33AM EDT  SCYNEXIS Announces FDA Granted BREXAFEMME Five Years Of Exclusivity Under GAIN Act   Benzinga
08:30AM EDT  -- BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total of 10 years of regulatory exclusivity -- BREXAFEMME also protected by composition-of-matter patent until 2035 -- Commercial launch update call is scheduled for Tuesday, June 29th @ 12pm ET   GlobeNewswire Inc
Jun 8, 2021
11:19AM EDT  Crestone Joins Antimicrobials Working Group   PR Newswire
Jun 7, 2021
09:59AM EDT  Aegis Capital Maintains Buy on SCYNEXIS, Lowers Price Target to $35   Benzinga
Jun 2, 2021
11:13AM EDT  Scynexis Inc. (SCYX) said that the U.S. Food and Drug Administration has approved Brexafemme or ibrexafungerp tablets, for oral use in patients with vulvovaginal candidiasis or VVC, also known as vaginal yeast infection.   RTTNews
10:38AM EDT  Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates   Benzinga
09:07AM EDT  Scynexis Scores FDA Nod For Brexafemme, Oral Treatment For Vaginal Yeast Infection   Benzinga
08:20AM EDT  The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements   Benzinga
07:55AM EDT  SCYNEXIS: FDA Approves BREXAFEMME For Oral Use In Patients With Vulvovaginal Candidiasis   RTTNews
07:30AM EDT  SCYNEXIS Announces FDA Approval Of BREXAFEMME   Benzinga
Jun 1, 2021
05:31PM EDT  Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates   Benzinga
May 18, 2021
04:15PM EDT  SCYNEXIS 8-K Shows Co. Deal For Issuance, Sale Of Shares With Cantor   Benzinga
May 17, 2021
10:24AM EDT  SCYNEXIS shares were trading lower after the company reported Q1 earnings results.   Benzinga
08:38AM EDT  SCYNEXIS Q1 EPS $(0.23) Up From $(0.72) YoY   Benzinga
08:30AM EDT  SCYNEXIS Reports First Quarter 2021 Financial Results and Provides   GlobeNewswire Inc
May 14, 2021
03:43PM EDT  Scynexis Raises $60M Via Term Loan Ahead Of Expected Approval Of Vaginal Yeast Infection Treatment   Benzinga
08:36AM EDT  SCYNEXIS Secures Term Loan Facility For Up To $60M With Hercules Capital And Silicon Valley Bank   Benzinga
08:30AM EDT  SCYNEXIS Secures Term Loan Facility for up to $60 Million with   GlobeNewswire Inc
May 11, 2021
08:30AM EDT  -- Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch   GlobeNewswire Inc
Apr 30, 2021
08:08AM EDT  SCYNEXIS Highlights Presentation Of Data At 2021 American College Of Obstetricians And Gynecologists Showing Outcome, Sustained Response Of Investigational Oral Ibrexafungerp In Difficult-To-Treat Patients With Vaginal Yeast Infections   Benzinga
08:00AM EDT  SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive   GlobeNewswire Inc
Apr 20, 2021
08:01AM EDT  SCYNEXIS Says To Present 2 Ibrexafungerp Posters At 2021 American College Of Obstetricians And Gynecologists Annual And Scientific Meeting   Benzinga
08:00AM EDT  SCYNEXIS to Present Two Ibrexafungerp   GlobeNewswire Inc
Apr 19, 2021
03:00PM EDT  SCYNEXIS Option Alert: Dec 17 $12.5 Calls Sweep (25) near the Ask: 209 @ $1.646 vs 0 OI; Earnings 5/10 Before Open [est] Ref=$7.43   Benzinga
Apr 12, 2021
12:56PM EDT  Aegis Capital Maintains Buy on SCYNEXIS, Lowers Price Target to $40   Benzinga
Mar 29, 2021
08:22AM EDT  SCYNEXIS FY20 EPS $(5.15), Up From $(9.58) YoY   Benzinga
08:20AM EDT  SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial   GlobeNewswire Inc
Mar 2, 2021
07:40AM EST  SCYNEXIS Announces Results From Interim Analyses Of Ongoing Phase 3 Studies Of Ibrexafungerp; Says Results Show 'positive clinical activity' Of Oral Ibrexafungerp In Patients With Fungal Infections   Benzinga
07:30AM EST  SCYNEXIS Announces Positive Results from Interim Analyses of   GlobeNewswire Inc
Feb 23, 2021
12:14PM EST  SCYNEXIS Shares Quiet; Brookline Capital Markets Lowers Price Target From $46 To $32   Benzinga
08:22AM EST  SCYNEXIS And Amplity Health Announce Agreement To Support The Anticipated US Commercialization Of BrexafemmeTM For Vaginal Yeast Infections   Benzinga
08:15AM EST  SCYNEXIS and Amplity Health Announce Agreement to Support the   GlobeNewswire Inc
Feb 17, 2021
10:44AM EST  SCYNEXIS Shares See Volume; Hearing MAXIM Raises Price Target To $22   Benzinga
10:04AM EST  UTILITY Therapeutics Joins Antimicrobials Working Group   PR Newswire
08:16AM EST  SCYNEXIS Announces Licensing Agreement And Partnership With Hansoh Pharma For Rights To Ibrexafungerp In Greater China; SCYNEXIS To Receive Up To $122M In Milestones With $10M Upfront And Low Double-Digit Royalties   Benzinga
08:15AM EST  SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China   Business Wire
08:15AM EST  -- Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, provides fully integrated R&D, manufacturing, and commercial capabilities to accelerate entry of ibrexafungerp in the global market   GlobeNewswire Inc
Feb 9, 2021
07:30AM EST  Aquestive Therapeutics Strengthens Board of Directors with   GlobeNewswire Inc
Jan 22, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 22, 2021   Benzinga
07:18AM EST  Guggenheim Initiates Coverage On SCYNEXIS with Buy Rating, Announces Price Target of $25   Benzinga
Jan 6, 2021
10:14AM EST  Benzinga's Top Upgrades, Downgrades For January 6, 2021   Benzinga
07:37AM EST  Cantor Fitzgerald Initiates Coverage On SCYNEXIS with Overweight Rating, Announces Price Target of $30   Benzinga
Jan 5, 2021
04:06PM EST  Hearing Cantor Fitzgerald Initiated Coverage On SCYNEXIS With Overweight Rating And $30 Price Target   Benzinga
Dec 28, 2020
09:05AM EST  9 Biggest Price Target Changes For Monday   Benzinga
06:52AM EST  HC Wainwright & Co. Reiterates Buy on SCYNEXIS, Lowers Price Target to $20   Benzinga
Dec 23, 2020
05:18PM EST  SCYNEXIS 13G Filing By Stonepine Capital Shows 7.7% Stake   Benzinga
11:35AM EST  Insider Buys SCYNEXIS Shares   Benzinga
Dec 22, 2020
08:00AM EST  SCYNEXIS Announces Closing of $85 Million Public Offering of   GlobeNewswire Inc
Dec 17, 2020
02:34PM EST  Mid-Afternoon Market Update: Dow Surges 130 Points; SCYNEXIS Shares Slide   Benzinga
12:28PM EST  Mid-Day Market Update: Gold Rises 1.7%; Triterras Shares Plummet   Benzinga
09:30AM EST  SCYNEXIS Announces Pricing Of $85M Public Offering Of Common Stock Priced At $6.25/Share   Benzinga
09:29AM EST  SCYNEXIS Announces Pricing of $85 Million Public Offering of   GlobeNewswire Inc
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 16, 2020
04:24PM EST  SCYNEXIS Announces The Launch of $50M Common Stock And Warrant Offering   Benzinga
04:21PM EST  SCYNEXIS Announces Launch of $50 Million Public Offering of Common   GlobeNewswire Inc
Dec 10, 2020
08:05AM EST  SCYNEXIS Reports Advanced Ibrexafungerp's Intravenous Formulation To Clinical Stage   Benzinga
08:00AM EST  -- Approval granted by health authority for the intravenous (IV) formulation of ibrexafungerp to enter Phase 1; dosingin healthy volunteersto start in the first quarter of 2021   GlobeNewswire Inc
Dec 7, 2020
08:01AM EST  SCYNEXIS Announces FDA Acceptance And Priority Review Of New Drug Application For Oral Ibrexafungerp For Treatment Of Vaginal Yeast Infections   Benzinga
08:00AM EST  -- 6-month Priority Reviewgranted for ibrexafungerp with PDUFA target action date set forJune 1, 2021   GlobeNewswire Inc
Nov 24, 2020
09:35AM EST  SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences   GlobeNewswire Inc
Nov 6, 2020
08:54AM EST  SCYNEXIS Q3 Loss/Shr $0.28 Vs Loss $1.45 Last Year   RTTNews
08:45AM EST  SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides   GlobeNewswire Inc
Oct 21, 2020
08:35AM EDT  SCYNEXIS To Present Ibrexafungerp Data At IDWeek 2020 Oct. 21-25   Benzinga
08:30AM EDT  SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp   GlobeNewswire Inc
Oct 14, 2020
08:33AM EDT  SCYNEXIS Announces Submission Of New Drug Application To FDA For Oral Ibrexafungerp For Treatment Of Vaginal Yeast Infection   Benzinga
08:30AM EDT  -- NDA submission is supported by positive data from twoPhase 3 studies(VANISH Program)in women with vulvovaginal candidiasis (VVC) -- Asa qualified infectious disease product (QIDP),ibrexafungerp is expected to receive a 6-month priority review following NDA acceptance   GlobeNewswire Inc
Oct 12, 2020
08:32AM EDT  SCYNEXIS To Present Two Posters Highlighting Ibrexafungerp For The Treatment Of Vaginal Yeast Infection At The 23rd Annual Premier Women's Healthcare Virtual Conference   Benzinga
08:30AM EDT  SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the   GlobeNewswire Inc
Sep 10, 2020
08:39AM EDT  SCYNEXIS to Participate in H.C. Wainwright Conference and   GlobeNewswire Inc
Aug 13, 2020
08:19AM EDT  SCYNEXIS Highlights Presentations On Ibrexafungerp's Potential For Treatment Of Vulvovaginal Candidiasis At Infectious Diseases Society for Obstetrics and Gynecology Meeting   Benzinga
08:00AM EDT  -- Two oral presentations by VVC experts on ibrexafungerp, one in-vitro activity study and one on VANISH-303 study -- SCYNEXIS to sponsor symposium: Current Challenges and Advancements in the Treatment of Vulvovaginal Candidiasis   GlobeNewswire Inc
Aug 10, 2020
08:23AM EDT  SCYNEXIS Q2 Net Loss $6.4 Mln Or $0.64/shr Vs Loss Of $8.4 Mln Or $1.58/shr Last Year   RTTNews
08:20AM EDT  In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal yeast infection. NDA submission for this indication remains on track for Q4 2020.   GlobeNewswire Inc
Jul 29, 2020
08:03AM EDT  SCYNEXIS Reports Successful Completion of Pre-NDA Meetings With FDA Regarding Ibrexafungerp For Treatment Of Vulvovaginal Candidiasis   Benzinga
08:00AM EDT  -- Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4 2020.   GlobeNewswire Inc
Jul 22, 2020
08:02AM EDT  SCYNEXIS Announces Four Posters Presented At ASM Microbe 2020 Highlighting Potential Clinical Utility Of Ibrexafungerp   Benzinga
08:00AM EDT  SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020   GlobeNewswire Inc
Jul 16, 2020
09:04AM EDT  SCYNEXIS Reports 1-For-10 Reverse Stock Split, Effective Jul. 17, 2020   Benzinga
09:00AM EDT  SCYNEXIS Announces One-for-Ten Reverse Stock Split   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC